CN104302669A - 抗cd98抗体及其使用方法 - Google Patents

抗cd98抗体及其使用方法 Download PDF

Info

Publication number
CN104302669A
CN104302669A CN201280067876.7A CN201280067876A CN104302669A CN 104302669 A CN104302669 A CN 104302669A CN 201280067876 A CN201280067876 A CN 201280067876A CN 104302669 A CN104302669 A CN 104302669A
Authority
CN
China
Prior art keywords
antibody
cancer
seq
people
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280067876.7A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·利平科特
爱德华·泰恩·顿·凡德霍斯特
约瑟夫·扎克維加
候昂·特朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igenica Inc
Original Assignee
Igenica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenica Inc filed Critical Igenica Inc
Publication of CN104302669A publication Critical patent/CN104302669A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280067876.7A 2011-11-23 2012-11-21 抗cd98抗体及其使用方法 Pending CN104302669A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563443P 2011-11-23 2011-11-23
US61/563,443 2011-11-23
PCT/US2012/066347 WO2013078377A1 (en) 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CN104302669A true CN104302669A (zh) 2015-01-21

Family

ID=47295209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280067876.7A Pending CN104302669A (zh) 2011-11-23 2012-11-21 抗cd98抗体及其使用方法

Country Status (15)

Country Link
EP (1) EP2782935A1 (pt)
JP (1) JP2015501639A (pt)
KR (1) KR20140125351A (pt)
CN (1) CN104302669A (pt)
AU (1) AU2012340623A1 (pt)
BR (1) BR112014012590A8 (pt)
CA (1) CA2856873A1 (pt)
HK (1) HK1202877A1 (pt)
IL (1) IL232755A0 (pt)
MX (1) MX2014006272A (pt)
PH (1) PH12014501164A1 (pt)
RU (1) RU2014124530A (pt)
SG (1) SG11201402619VA (pt)
WO (1) WO2013078377A1 (pt)
ZA (1) ZA201403760B (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138172A (zh) * 2015-08-10 2018-06-08 国立大学法人大阪大学 抗体
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
CN109562170A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109562168A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109562169A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
WO2022252167A1 (en) * 2021-06-02 2022-12-08 Huahui Health Ltd. Anti-cd98 antibodies and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
WO2014197871A2 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-drug conjugates, compositions and methods of use
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
RU2017120039A (ru) * 2014-12-10 2019-01-10 Дженентек, Инк. Антитела к рецепторам гематоэнцефалического барьера и способы их применения
CN116284404A (zh) 2016-06-08 2023-06-23 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
EP3715370A1 (en) * 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
WO2021205361A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Anti-cd98 antibodies and uses thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN115772541A (zh) * 2021-12-17 2023-03-10 百奥赛图江苏基因生物技术有限公司 Cd98hc基因人源化非人动物的构建方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110280884A1 (en) * 2006-04-06 2011-11-17 Kirin Pharma Kabushiki Kaisha Anti-cd98 antibody

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
JP4578098B2 (ja) 2001-10-01 2010-11-10 ダイアックス、コープ 多重鎖真核ディスプレイベクターとその使用
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
JPWO2011118804A1 (ja) * 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110280884A1 (en) * 2006-04-06 2011-11-17 Kirin Pharma Kabushiki Kaisha Anti-cd98 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAELA GEBAUER ET AL.: "Engineered protein scaffolds as next-generation antibody therapeutic", 《CURRENT OPINION IN CHEMICAL BIOLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138172A (zh) * 2015-08-10 2018-06-08 国立大学法人大阪大学 抗体
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
CN109562170A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109562168A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109562169A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109562170B (zh) * 2016-06-08 2023-01-13 艾伯维公司 抗cd98抗体及抗体药物偶联物
WO2022252167A1 (en) * 2021-06-02 2022-12-08 Huahui Health Ltd. Anti-cd98 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2013078377A9 (en) 2013-08-08
MX2014006272A (es) 2014-10-24
IL232755A0 (en) 2014-07-31
NZ626513A (en) 2017-02-24
JP2015501639A (ja) 2015-01-19
WO2013078377A1 (en) 2013-05-30
HK1202877A1 (en) 2015-10-09
PH12014501164A1 (en) 2014-10-20
RU2014124530A (ru) 2015-12-27
CA2856873A1 (en) 2013-05-30
AU2012340623A1 (en) 2014-07-17
EP2782935A1 (en) 2014-10-01
ZA201403760B (en) 2017-09-27
SG11201402619VA (en) 2014-10-30
BR112014012590A2 (pt) 2017-06-20
KR20140125351A (ko) 2014-10-28
BR112014012590A8 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
CN104302669A (zh) 抗cd98抗体及其使用方法
CN101437852B (zh) 抗tat226抗体和免疫偶联物
US20150231240A1 (en) Anti-c16orf54 antibodies and methods of use thereof
JP2021120382A (ja) 部位特異的抗体コンジュゲーション方法および組成物
CN104710532B (zh) 人源化的抗-β7拮抗剂及其应用
JP5723392B2 (ja) 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
CN102378767B (zh) 抗-fgfr3抗体及其使用方法
CN103547597B (zh) 新型调节剂及使用方法
ES2527521T3 (es) Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
RU2613886C2 (ru) Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
US20140050661A1 (en) Novel anti-cxcr4 antibodies and their use for the treatment of cancer
CN107108740A (zh) 抗fgfr2/3抗体及其使用方法
ES2469369T3 (es) Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer
CN104334580A (zh) 抗sez6抗体及使用方法
JP2010528056A (ja) がん細胞の細胞殺作用を媒介するヒト化抗ｔｒｏｐ−２抗体とキメラ抗ｔｒｏｐ−２抗体
CN116410318A (zh) 抗axl拮抗抗体
TW200825105A (en) Antibodies and immunoconjugates and uses therefor
JP2011515069A (ja) 造血系起源の腫瘍の治療のための組成物と方法
SG185583A1 (en) Anti-human trop-2 antibody having antitumor activity in vivo
CN103755809B (zh) 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
JP2016538318A (ja) 新規ｓｅｚ６モジュレーターおよび使用方法
WO2015161247A1 (en) Humanized anti-c16orf54 antibodies and methods of use thereof
CN101687930A (zh) 介导癌细胞细胞毒性的嵌合和人源化抗cd44抗体
CN103201290A (zh) S100a4抗体及其治疗用途
KR20090130335A (ko) 암 세포 세포독성을 매개하는 인간화 및 키메라 항-ｃｄ５９ 항체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150121